ClinicalTrials.gg
CompletedNCT03556436Updated Jan 16, 2019

Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448

A Phase 1 interventional study of YH25448 240mg in Non-Small Cell Lung Cancer, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-16.

Sponsored by Yuhan Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 11 under way, 2 of them phase 3. lazertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
19th of 20
24 · median 67
Started
2018
the only one that year
Phase 1
3 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
4 of 20
Yuhan Corporation

Among the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by enrollment, is the only one that started in 2018, is one of 3 in phase 1, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About lazertinib

lazertinib: first FDA approval 2024 (LAZCLUZE), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Clinical trial is to evaluate the effect of ethnicity and food on the pharmacokinetics (how a drug is absorbed, metabolized, distributed and excreted; plasma drug concentration will be measured in this clinical trial) of YH25448, which Yuhan Corporation plans to develop as a therapeutic agent for Non-Small Cell Lung Cancer.

Read the detailed description

This clinical trial will be conducted in healthy Korean and Caucasian volunteers at Seoul National University Hospital (SNUH) Clinical Trial Center.

It is expected to take approximately 39 days from the first dosing of Investigational Product until the final follow-up visit. It will be hospitalized twice for 9 nights and 10 days with 21 days of interval, and one visit will be needed for safety evaluation between 14-17 days from the last dosing of the Investigational Product.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • YH25448
  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Informed of the nature of this study and voluntarily agree to participate in this study.
  2. Subjects with range of ≥18.5 kg/m2 and \< 30.0 kg/m2 and weighing ≥ 50 kg
  3. Subjects without congenital or chronic diseases within the last 3 years and without pathologic symptoms as determined by medical diagnosis
  4. Healthy Korean and Caucasian males who aged ≥ 19 and ≤ 55 years at the time of consent

Exclusion criteria

Exclusion Criteria:

  1. chronic infection (e.g. AIDS) or clinically significant medical or psychiatric illness
  2. Hypotension (SBP ≤ 90 mmHg or DBP ≤ 50 mmHg) or hypertension (SBP ≥ 150 mmHg or DBP ≥ 100 mmHg)
  3. A marked baseline prolongation of greater than 450 msec by Bazett's formula
  4. Within 14 days prior to the first administration of product, use of prescription drugs or herbal medication, or within 7 days use of any over-the-counter medications
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1

    YH25448 240mg single dose in korean

    Drug: YH25448 240mg

  • Experimental
    Group 2

    YH25448 240mg single dose in caucasian

    Drug: YH25448 240mg

Interventions

  • period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast

    Also known as: YH25448

06

What researchers measure

Primary outcomes

  1. AUClast of YH25448

    Area under the plasma concentration-time curve from zero to the time of the last quantitative concentration (AUC) of YH25448

    Time frame: 0-192 hrs

  2. Cmax of YH25448

    Area under the plasma concentration-time curve from zero to the time of Maximum plasma concentration (Cmax) of YH25448

    Time frame: 0-192 hrs

Secondary outcomes

  1. AUCinf of YH25448

    Area under the plasma concentration time curve from zero to infinity (AUC) of YH25448

    Time frame: 0-192 hrs

  2. Tmax of YH25448

    Time to reach Cmax of YH25448

    Time frame: 0-192 hrs

  3. t1/2 of YH25448

    Terminal half life (t1/2) of YH25448

    Time frame: 0-192 hrs

  4. CL/F of YH25448

    The apparent plasma clearance (CL/F) of YH25448

    Time frame: 0-192 hrs

  5. Vd/F of YH25448

    Apparent Volume of distribution of YH25448

    Time frame: 0-192 hrs

07

Study locations

1 site
  • Seoul National University Hospital Clinical Trial Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Dec 2018, 5 months.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 5 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2018
First posted
Jun 14, 2018
StartActual
Jul 3, 2018
Primary completionActual
Dec 30, 2018
CompletionActual
Dec 30, 2018
Last update
Jan 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03556436
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Jun 14, 2018
Start date
Jul 3, 2018
Primary completion
Dec 30, 2018
Completion
Dec 30, 2018
Last update
Jan 16, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lazertinib

Start the discussion